Volcon (NASDAQ:VLCN) has announced the closing of its previously announced securities purchase agreements for the purchase and sale of 3.29M shares of common stock and/or pre-funded warrants to acquire common stock in a registered direct offering. The purchase price of each share was $3.65. The purchase price for the pre-funded warrantsContinue Reading
teddyleung/iStock Editorial via Getty Images Volkswagen (VWAGY, VWAPY) shares closed 1.4% lower Tuesday as selling pressure was triggered after the company said its Brussels facility which manufactures the Audi Q8 e-tron EV model could be shuttered due to lackluster demand for the vehicle. The expenses incurred to close the facility,Continue Reading
Robert Way The EU is prepping a proposal to impose import duties on cheap products bought from online platforms outside the region, Bloomberg News reported. The move would mainly target Chinese firms such as Temu, owned by PDD (PDD), Alibaba’s (BABA) AliExpress, and Shein, the report added citing people withContinue Reading
Stock index futures ticked higher on Wednesday, a day after Nasdaq and S&P 500 closed at record highs. The stock market will close early at 1 p.m. ET and the bond market will close at 2 p.m. ET ahead of the July 4 holiday. But even with the shortened tradingContinue Reading
Justin Sullivan/Getty Images News Life Time Group Holdings (NYSE:LTH) announced on Monday that it closed on a sale-leaseback transaction for two properties, totaling $90 million in gross proceeds. The company noted that the transaction brings its total gross proceeds from sale-leasebacks to $130 million year-to-date. Life Time (LTH) is alsoContinue Reading
Augustine Therapeutics on Wednesday announced it has raised EUR 17M ($18.5M) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company and Charcot-Marie-Tooth Research Foundation. The proceeds from this first close will be used to advance Augustine’sContinue Reading
manassanant pamai Augustine Therapeutics, focused on novel treatments for neurodegenerative and cardio metabolic diseases, Wednesday said that it has raised €17 million ($18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company (NYSE:LLY), and theContinue Reading
